TECHNOLOGY MIP TECHNOLOGY OUR PUBLICATIONS APPLICATIONS SENSORS IVD ASSAYS SIMPLIFIED WORKFLOW PRODUCTS COVID-19 IN DEVELOPMENT SERVICES CUSTOM MIP DEVELOPMENT EPITOPE DISCOVERY RESOURCES NEWS EVENTS ABOUT ABOUT US BOARD OF DIRECTORS MANAGEMENT TEAM April 15, 2021 Mike Dalrymple joins MIP Diagnostics as Head of Global Business Development
We are pleased to announce the appointment of Mike Dalrymple to the role of Head of Global Business Development at MIP Diagnostics on a consultancy basis.
With over 30 years’ experience in diagnostics and therapeutics, Mike brings a wealth of knowledge and expertise to the business. Mike has a long track record of driving new opportunities and executing high value deals, with previous roles at PPL Therapeutics, Virogen and, most recently, LifeArc as Executive Director of Diagnostics and Science Foresight. He is also a member of the Advisory Board for the Scottish Life Science Association.
As Head of Global Business Development, Mike will be focused on identifying new opportunities to support MIP Diagnostics’ ambitious growth plans. With significant experience in generating deals in the antibody space, Mike is well positioned to demonstrate the capabilities of molecularly imprinted polymers (MIPs) as synthetic alternatives to antibodies in IVD assays and other applications.
Speaking of the new role, Mike said, ‘Molecularly Imprinted polymer technology is extremely exciting since it can enable new applications where antibodies have previously reached their limits. I am delighted to join the business during a time of rapid growth and look forward to securing new opportunities as we progress through 2021.’
Please get in touch if you would like to arrange an introductory call with Mike at enquiries@mip-dx.com